drugset / Trial / NCT02183480

Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers

NCT02183480

Phase 1 Completed 12 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to assess the pharmacokinetics and dose proportionality of 1 mg, 2.5 mg and 5 mg tablets of linagliptin

Timeline

Start
2009-07
Primary completion
2009-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 1 mg Oral
Subject Linagliptin Small molecule 2.5 mg Oral
Subject Linagliptin Small molecule 5 mg Oral

Indications

No indication recorded.